Bavarian Nordic Receives Contract From Janssen As Part Of Ebola Vaccine Regimen
News Sep 16, 2015
Bavarian Nordic A/S has announced the award of a subcontract from Crucell Holland B.V., one of Janssen Pharmaceutical Companies of Johnson & Johnson, valued at USD 9 million. This is part of a contract awarded to Janssen by the U.S. Biomedical Advanced Research and Development Authority (BARDA) to support the advanced development and manufacturing of the Ebola prime-boost vaccine regimen which consists of Bavarian Nordic’s MVA-BN® Filo and Ad26.ZEBOV from Janssen.
The five-year base subcontract covers studies to improve the manufacturing process and establish long-term storage of MVA-BN Filo bulk vaccine. The contract also includes options for an additional USD 24 million to implement process development activities for formulation of a final drug product with a longer shelf life.
As part of an accelerated development program, Janssen has initiated multiple clinical studies of the prime-boost Ebola vaccine regimen in Europe and Africa. By awarding a contract to Janssen, BARDA is prioritizing the rapid development of this promising vaccine regimen candidate. To date, Bavarian Nordic has produced and delivered the bulk equivalent of over one million doses of its vaccine.
Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: “We are very pleased to strengthen our collaboration with Janssen on the accelerated development of the prime-boost Ebola vaccine regimen. More importantly, it is encouraging that the U.S. Government - through BARDA, with whom we have worked for over a decade - recognizes the potential of this vaccine to build international preparedness for current and future Ebola outbreaks.”
As the majority of revenue from the contract will be recognized in 2016 and 2017, no changes are made in the Company’s expectations for the financial results for 2015.
H7N9 Influenza Vaccine Clinical Trials CommenceNews
Two new clinical trials testing an experimental vaccine to prevent influenza caused by an H7N9 influenza virus are now enrolling volunteers at sites across the United States. The Phase 2 studies will test different dosages of the inactivated influenza vaccine candidate as well as different vaccination schedules. The studies also will evaluate whether an adjuvant boosts the immune responses of people receiving the vaccine.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE